|Title:||Use of HDAC inhibitors for the treatment of myeloma|
|Abstract:|| The present invention relates to the use of an HDAC inhibitor, especially an HDAC inhibitor of formula (I) ##STR00001## wherein the radicals and symbols have the meanings as defined in the specification, for the preparation of a medicament for the treatment of myeloma, in particular, multiple myeloma, especially myeloma which is resistant to conventional chemotherapy; to a combination comprising an HDAC inhibitor and a compound effecting apoptosis of myeloma cells, preferably bortezomib, for simultaneous, separate or sequential use; to methods of treating myeloma; and to a pharmaceutical composition comprising said combination.|
|Inventor(s):|| Atadja; Peter W (Acton, MA) |
|Assignee:|| Novartis AG (Basel, CH) |
1. A method of treating multiple myeloma in a human patient in need thereof comprising administering in an amount which is synergistically effective, a combination of
N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol3-yl)-ethyl]-amino]methyl]phenyl]-2- E-2-propenamide having the formula (III) ##STR00013## or a pharmaceutically acceptable salt thereof and bortezomib or a pharmaceutically acceptable salt thereof, wherein the
multiple myeloma is resistant to conventional therapy.
2. The method of claim 1, wherein the multiple myeloma is resistant to bortezomib.